NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)
NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM
NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
NCT01677858: Phase 1/2: Weekly Carfilzomib + Dex for Progressive Multiple Myeloma (CHAMPION 1)
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
NCT01712789: Phase 3 - Pomalidomide + Dex (Low Dose) Refractory or Relapsed Multiple Myeloma STRATUS
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide & Low-Dose Dexamethasone in RRMM Myeloma
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
NCT01134484: Phase 3 - VELCADE-Thal-Dex (VTD) vs Thal-Dex (TD) Incorporated Into Double ASCT NDMM